Shanghai Fosun Pharmaceutical (02196): Phase III clinical trial of FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria initiated in China
Shanghai Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical Development Co., Ltd. (hereinafter referred to as the "Company"), a controlled subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company"), has initiated a Phase III clinical trial in China for FXS6837 capsules (formerly project code: XH-S003, hereinafter referred to as "FXS6837") for the treatment of paroxysmal nocturnal hemoglobinuria.
Shanghai Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company"), through its controlled subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., initiated a Phase III clinical trial in China for FXS6837 capsules (formerly project code: XH-S003, hereinafter referred to as "FXS6837") for the treatment of paroxysmal nocturnal hemoglobinuria.
Related Articles
UNITED LAB (03933): Marketing registration application for semaglutide injection accepted
BRII-B (02137) repurchased 320,000 shares on November 4 for approximately HK$322,200.
Sanofi (SNY.US) Halts STAT6 Program; Nurix (NRIX.US) Falls Over 30% in Pre-Market! Milestone Payments and Revenue Sharing Both Fall Through
UNITED LAB (03933): Marketing registration application for semaglutide injection accepted
BRII-B (02137) repurchased 320,000 shares on November 4 for approximately HK$322,200.
Sanofi (SNY.US) Halts STAT6 Program; Nurix (NRIX.US) Falls Over 30% in Pre-Market! Milestone Payments and Revenue Sharing Both Fall Through
